PL2104682T3 - Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych - Google Patents
Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnychInfo
- Publication number
- PL2104682T3 PL2104682T3 PL08719192T PL08719192T PL2104682T3 PL 2104682 T3 PL2104682 T3 PL 2104682T3 PL 08719192 T PL08719192 T PL 08719192T PL 08719192 T PL08719192 T PL 08719192T PL 2104682 T3 PL2104682 T3 PL 2104682T3
- Authority
- PL
- Poland
- Prior art keywords
- alzheimer
- diagnosis
- treatment
- neurodementing
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88451307P | 2007-01-11 | 2007-01-11 | |
US88452607P | 2007-01-11 | 2007-01-11 | |
EP07000521A EP1944315A1 (en) | 2007-01-11 | 2007-01-11 | Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases |
EP07000507A EP1944314A1 (en) | 2007-01-11 | 2007-01-11 | Diagnosis of Alzheimer's disease and other neurodementing disorders |
US98166707P | 2007-10-22 | 2007-10-22 | |
US98167507P | 2007-10-22 | 2007-10-22 | |
EP07119002 | 2007-10-22 | ||
EP07119026 | 2007-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2104682T3 true PL2104682T3 (pl) | 2017-03-31 |
Family
ID=39609117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08719192T PL2104682T3 (pl) | 2007-01-11 | 2008-01-11 | Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych |
Country Status (11)
Country | Link |
---|---|
US (3) | US7939075B2 (pl) |
EP (1) | EP2104682B1 (pl) |
JP (1) | JP2010515717A (pl) |
AU (1) | AU2008204335B2 (pl) |
CA (1) | CA2675340C (pl) |
DK (1) | DK2104682T3 (pl) |
ES (1) | ES2610474T3 (pl) |
PL (1) | PL2104682T3 (pl) |
SI (1) | SI2104682T1 (pl) |
TW (1) | TW200844110A (pl) |
WO (1) | WO2008084402A2 (pl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090280114A1 (en) * | 2002-04-12 | 2009-11-12 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
EP2143447A1 (en) * | 2008-07-11 | 2010-01-13 | Universität Konstanz | Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease |
PT2398500T (pt) * | 2009-02-20 | 2019-06-14 | 2 Bbb Medicines B V | Sistema de entrega de medicamentos à base de glutationas |
KR101095630B1 (ko) * | 2009-06-17 | 2011-12-19 | 주식회사 이노파마스크린 | 베타 아밀로이드 펩타이드와 vegf의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제 |
DE102009034119A1 (de) * | 2009-07-20 | 2011-01-27 | Philipps-Universität Marburg | Verfahren, insbesondere Enzyme-linked Immunosorbent Assay (ELISA), zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit |
EP3296295A1 (en) | 2009-08-07 | 2018-03-21 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
RS53496B1 (en) * | 2011-10-04 | 2015-02-27 | Affiris Ag | PROCEDURE FOR THE DETECTION OF Aβ-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE |
KR101190573B1 (ko) * | 2011-10-07 | 2012-10-18 | 대한민국 | 혈액 내 아밀로이드-베타 항체에 특이적으로 결합하는 신규 Aβ22(pE)-42 펩티드를 유효성분으로 포함하는 치매 진단용 키트 |
EP2825884A4 (en) * | 2012-03-13 | 2015-11-11 | Janssen Alzheimer Immunotherap | A OLIGOMER FOR DIAGNOSIS, PROGNOSIS AND FOLLOW-UP OF ALZHEIMER'S DISEASE |
AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
US10942190B2 (en) | 2014-01-21 | 2021-03-09 | Shimadzu Corporation | Measurement method for amyloid precursor protein cleavage peptides |
WO2016054114A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
ES2663623T3 (es) * | 2015-01-12 | 2018-04-16 | Heraeus Deutschland GmbH & Co. KG | Uso de una composición eléctricamente conductora como adhesivo eléctricamente conductor para conectar mecánica y eléctricamente conductores eléctricos con los contactos eléctricos de células solares |
EP3324186B1 (en) | 2016-11-21 | 2020-09-16 | Ruhr-Universität Bochum | Method for the preselection of drugs for protein misfolding diseases |
EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SUBSTITUTION MOLECULES AND THEIR USES |
AU2018393076A1 (en) | 2017-12-19 | 2020-07-02 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
CA3085596A1 (en) * | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-frizzled antibodies and methods of use |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
EP0683234B2 (en) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
DK0994728T3 (da) | 1997-04-09 | 2008-12-01 | Intellect Neurosciences Inc | Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
EP1237930B1 (en) | 1999-12-08 | 2006-11-08 | Intellect Neurosciences, Inc. | Chimeric amyloid beta peptides |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
EP1257584B2 (en) | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
US20030083277A1 (en) | 2000-02-24 | 2003-05-01 | Hersh Louis B. | Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients |
KR101155294B1 (ko) * | 2000-06-16 | 2013-03-07 | 캠브리지 안티바디 테크놀로지 리미티드 | 면역특이적으로 BLyS에 결합하는 항체 |
EP1172378A1 (en) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US20020009445A1 (en) | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
US20050208050A1 (en) * | 2001-11-09 | 2005-09-22 | Gerd Multhaup | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
AU2002366355A1 (en) | 2001-12-17 | 2003-06-30 | New York State Office Of Mental Health | SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1911765A3 (en) | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation |
DE60336848D1 (de) | 2002-09-12 | 2011-06-01 | Univ California | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz |
WO2005025516A2 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
AU2003279728B2 (en) | 2002-10-01 | 2007-09-27 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
WO2004032868A2 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
US20050106626A1 (en) | 2002-10-20 | 2005-05-19 | George Pieczenik | Ligand binding of amyloid peptide protein epitope |
PL217296B1 (pl) * | 2002-11-15 | 2014-07-31 | Genmab As | Wyizolowane ludzkie przeciwciało monoklonalne, wytwarzająca je hybrydoma, kodujący to przeciwciało wektor ekspresyjny i zawierająca je kompozycja farmaceutyczna, immunokoniugat, bispecyficzna lub multispecyficzna cząsteczka obejmująca kwasy nukleinowe kodujące ciężki i lekki łańcuch transfektoma, ich zastosowania, zwłaszcza w medycynie, obejmująca te kwasy ex vivo eukariotyczna lub prokariotyczna komórka gospodarza oraz nie będące człowiekiem zwierzę transgeniczne lub roślina, sposób in vitro hamowania wzrostu i/lub proliferacji komórek wyrażających CD25 lub eliminowania komórek wyrażających CD25, sposób wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25, zestaw diagnostyczny do wykrywania w próbce obecności antygenu CD25 lub komórki wyrażającej CD25 |
US20070010435A1 (en) | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
JP4869074B2 (ja) * | 2003-11-28 | 2012-02-01 | アストラゼネカ アーベー | 抗体 |
UA93181C2 (ru) | 2004-02-23 | 2011-01-25 | Эли Лилли Энд Компани | СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
WO2006017173A1 (en) | 2004-07-10 | 2006-02-16 | Alexion Pharmaceuticals, Inc. | Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby |
CA2583017A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
AU2005306997B2 (en) * | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
EP1838349A1 (en) * | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
US7973140B2 (en) * | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
MX2007009091A (es) | 2005-01-28 | 2008-01-11 | Wyeth Corp | Formulaciones de polipeptido liquidas estabilizadas. |
KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 a-베타 올리고머의 정제 방법,당해 비확산성 a-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
CA2630964A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of alzheimer's and related diseases |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
EP2361638B1 (en) | 2005-12-12 | 2014-01-15 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
JP5033868B2 (ja) | 2006-03-23 | 2012-09-26 | バイオアークティック ニューロサイエンス アーベー | 改良型プロトフィブリル選択的抗体及びその使用 |
EP2114984A2 (en) * | 2007-01-17 | 2009-11-11 | Merck Serono S.A. | Process for the purification of fc-containing proteins |
HUE031944T2 (en) * | 2008-02-08 | 2017-08-28 | Immunas Pharma Inc | Antibodies capable of specific binding of amyloid β-oligomers and their use |
-
2008
- 2008-01-11 DK DK08719192.0T patent/DK2104682T3/en active
- 2008-01-11 SI SI200831731A patent/SI2104682T1/sl unknown
- 2008-01-11 TW TW097101288A patent/TW200844110A/zh unknown
- 2008-01-11 EP EP08719192.0A patent/EP2104682B1/en active Active
- 2008-01-11 JP JP2009545252A patent/JP2010515717A/ja active Pending
- 2008-01-11 WO PCT/IB2008/000456 patent/WO2008084402A2/en active Application Filing
- 2008-01-11 ES ES08719192.0T patent/ES2610474T3/es active Active
- 2008-01-11 AU AU2008204335A patent/AU2008204335B2/en not_active Ceased
- 2008-01-11 PL PL08719192T patent/PL2104682T3/pl unknown
- 2008-01-11 CA CA2675340A patent/CA2675340C/en active Active
- 2008-01-11 US US12/013,185 patent/US7939075B2/en active Active
-
2011
- 2011-04-05 US US13/079,852 patent/US8491903B2/en active Active
- 2011-04-05 US US13/079,886 patent/US20120040382A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2675340C (en) | 2018-07-31 |
US20120040382A1 (en) | 2012-02-16 |
JP2010515717A (ja) | 2010-05-13 |
AU2008204335A1 (en) | 2008-07-17 |
US8491903B2 (en) | 2013-07-23 |
WO2008084402A3 (en) | 2009-04-09 |
EP2104682B1 (en) | 2016-09-21 |
US7939075B2 (en) | 2011-05-10 |
TW200844110A (en) | 2008-11-16 |
SI2104682T1 (sl) | 2017-05-31 |
DK2104682T3 (en) | 2017-01-16 |
WO2008084402A2 (en) | 2008-07-17 |
US20090028869A1 (en) | 2009-01-29 |
US20120039897A1 (en) | 2012-02-16 |
AU2008204335B2 (en) | 2013-06-13 |
CA2675340A1 (en) | 2008-07-17 |
ES2610474T3 (es) | 2017-04-27 |
WO2008084402A8 (en) | 2009-08-27 |
EP2104682A2 (en) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2104682T3 (pl) | Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych | |
EP2001503A4 (en) | DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER | |
IL208926A0 (en) | Use of epothelone d in treating tau-associated diseases including alzheimer's disease | |
EP2369017B8 (en) | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases | |
EP1951892A4 (en) | ANTIBODY TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
ZA200801511B (en) | Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases | |
EP2429992A4 (en) | TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER | |
EP2152318A4 (en) | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE | |
EP2151435A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
EP1817050A4 (en) | DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER | |
EP2091566A4 (en) | COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES | |
PT2056842E (pt) | Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais | |
EP2297341A4 (en) | METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON | |
EP2268647A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
EP1962869A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
SI2056863T1 (sl) | Zdravljenje očesnih bolezni | |
EP2306824A4 (en) | IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER | |
EP2051732A4 (en) | DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR | |
GB0608647D0 (en) | Methods of diagnosis and treatment | |
PL1981515T3 (pl) | Leczenie urazów i chorób mózgu za pomocą MAPC | |
EP2568811A4 (en) | TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER | |
EP2320939A4 (en) | TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE | |
IL213703A (en) | Compounds for the treatment of pain and other diseases | |
EP1773882A4 (en) | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6 | |
WO2010105035A9 (en) | Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure |